Research and Markets: Niche Markets and Rare Diseases: Idiopathic Pulmonary Fibrosis
Research and Markets (http://www.researchandmarkets.com/research/67bvkk/niche_markets_and) has announced the addition of Decision Resources, Inc's new report "Niche Markets and Rare Diseases: Idiopathic Pulmonary Fibrosis" to their offering.
Idiopathic pulmonary fibrosis (IPF) is one of the most common interstitial lung diseases (ILDs) and is the most prevalent pulmonary fibrotic disease. IPF is associated with high morbidity and mortality; mean survival following diagnosis is two years. Until 2011, no drugs were licensed for IPF in either the United States or Europe; pirfenidone (InterMune's Esbriet) launched in Germany in September 2011. In addition, no disease-modifying drug therapies are strongly recommended in the 2011 guidelines on IPF management. Guidelines recommend IPF cases be considered for lung transplant, given the absence of any drug therapies to improve their condition. Several pharmaceutical developers are investing in developing treatments for IPF; five new agents are poised for approval for use in IPF over the 2010-2020 forecast period.
Key Topics Covered:
Key Parameters of the Idiopathic Pulmonary Fibrosis Market
Market Share of Key Drug Classes, 2015 and 2020
Drug Development Activity
What Do The Experts Say?
Key Challenges & Opportunities
The Role of Inflammation
Physician Opinion on the Role of Inflammation
Signaling Molecules as Drug Targets
Recent Failures in Drug Trials
Diagnosed Prevalent Cases
Diagnosed Prevalent Cases, by Age and Severity
Patient Population Methods
Current Therapies and Medical Practice
Trends in Diagnosis
Diagnosis and Referral Patterns: United States
and much more...
For more information visit http://www.researchandmarkets.com/research/67bvkk/niche_markets_and
Source: Decision Resources, Inc